Making the Most of Anti-Androgen Therapies in Prostate Cancer Through Pharmacist Interventions

This program is 1 of 3 virtual symposia offered in partnership with HOPA that include patient counseling videos to demonstrate “best practice” pharmacist communication with patients.

Program Description

Treatment strategies for patients with prostate cancer focus on lowering circulating androgen levels. Anti-androgens were initially approved for metastatic, castration-resistant disease but are now being introduced earlier in the disease course. As the landscape of therapies for prostate cancer continues to expand, oncology pharmacists will need to be familiar with evolving guideline recommendations for therapy in patients with castration-naïve and castration-resistant disease. This activity will review clinical trial data supporting use of anti-androgen therapies earlier in the disease course in patients with hormone-sensitive (castration-naïve) disease as well as emerging therapies including combination strategies with PARP inhibitors. Patient counseling video vignettes accompanying this program will review the importance of adherence, management of adverse effects, and details of administration of anti-androgen therapies oncology pharmacists should emphasize when counseling individuals with prostate cancer.

Target audience: Oncology pharmacists
Type of activity: Application
Release date: December 21, 2022
Expiration date: December 21, 2023
Time to complete activity: 1.25 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Investigate unique pharmacologic features among novel anti-androgens in the treatment of prostate cancer
• Apply guideline recommendations to incorporate anti-androgens safely and effectively into individualized prostate cancer treatment strategies
• Optimize management of common and serious toxicities of anti-androgen treatments through early recognition, accurate grading, and appropriate treatment strategies
• Examine solutions to medication nonadherence in patients with prostate cancer based on barriers to medication adherence

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.25 contact hours (0.125 CEU) under the ACPE universal activity number 0290-0000-22-624-H01-P. The activity is available for CE credit through December 21, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Sherry L. Vogt, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Seung, PharmD, BCOP, FHOPA; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms